uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress

Barchart · 6d ago

~ AMT-130 granted Breakthrough Therapy designation by FDA ~

~ Initial safety data from third cohort of Phase I/II study show AMT-130 continues to be generally well-tolerated, with no treatment-related serious adverse events ~

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.